These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 24978026)
1. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients. Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026 [TBL] [Abstract][Full Text] [Related]
2. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone. Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090 [TBL] [Abstract][Full Text] [Related]
3. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318 [TBL] [Abstract][Full Text] [Related]
4. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430 [TBL] [Abstract][Full Text] [Related]
5. Genetic predisposition to ductal carcinoma in situ of the breast. Petridis C; Brook MN; Shah V; Kohut K; Gorman P; Caneppele M; Levi D; Papouli E; Orr N; Cox A; Cross SS; Dos-Santos-Silva I; Peto J; Swerdlow A; Schoemaker MJ; Bolla MK; Wang Q; Dennis J; Michailidou K; Benitez J; González-Neira A; Tessier DC; Vincent D; Li J; Figueroa J; Kristensen V; Borresen-Dale AL; Soucy P; Simard J; Milne RL; Giles GG; Margolin S; Lindblom A; Brüning T; Brauch H; Southey MC; Hopper JL; Dörk T; Bogdanova NV; Kabisch M; Hamann U; Schmutzler RK; Meindl A; Brenner H; Arndt V; Winqvist R; Pylkäs K; Fasching PA; Beckmann MW; Lubinski J; Jakubowska A; Mulligan AM; Andrulis IL; Tollenaar RA; Devilee P; Le Marchand L; Haiman CA; Mannermaa A; Kosma VM; Radice P; Peterlongo P; Marme F; Burwinkel B; van Deurzen CH; Hollestelle A; Miller N; Kerin MJ; Lambrechts D; Floris G; Wesseling J; Flyger H; Bojesen SE; Yao S; Ambrosone CB; Chenevix-Trench G; Truong T; Guénel P; Rudolph A; Chang-Claude J; Nevanlinna H; Blomqvist C; Czene K; Brand JS; Olson JE; Couch FJ; Dunning AM; Hall P; Easton DF; Pharoah PD; Pinder SE; Schmidt MK; Tomlinson I; Roylance R; García-Closas M; Sawyer EJ Breast Cancer Res; 2016 Feb; 18(1):22. PubMed ID: 26884359 [TBL] [Abstract][Full Text] [Related]
6. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ. Davis JE; Nemesure B; Mehmood S; Nayi V; Burke S; Brzostek SR; Singh M Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):20-5. PubMed ID: 26317313 [TBL] [Abstract][Full Text] [Related]
7. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling. Shen KL; Harn HJ; Ho LI; Yu CP; Chiu SC; Lee WH Cancer; 1998 Jun; 82(12):2373-81. PubMed ID: 9635530 [TBL] [Abstract][Full Text] [Related]
8. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression. Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637 [TBL] [Abstract][Full Text] [Related]
9. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886 [TBL] [Abstract][Full Text] [Related]
10. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Muggerud AA; Hallett M; Johnsen H; Kleivi K; Zhou W; Tahmasebpoor S; Amini RM; Botling J; Børresen-Dale AL; Sørlie T; Wärnberg F Mol Oncol; 2010 Aug; 4(4):357-68. PubMed ID: 20663721 [TBL] [Abstract][Full Text] [Related]
11. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers. Rehman S; Crow J; Revell PA Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657 [TBL] [Abstract][Full Text] [Related]
12. Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue. Hartmann K; Schlombs K; Laible M; Gürtler C; Schmidt M; Sahin U; Lehr HA Diagn Pathol; 2018 Oct; 13(1):83. PubMed ID: 30342538 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast. Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981 [TBL] [Abstract][Full Text] [Related]
14. Is there a low-grade precursor pathway in breast cancer? King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747 [TBL] [Abstract][Full Text] [Related]
15. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications. Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752 [TBL] [Abstract][Full Text] [Related]
16. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade. Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189 [TBL] [Abstract][Full Text] [Related]
17. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component. Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370 [TBL] [Abstract][Full Text] [Related]
19. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. Heselmeyer-Haddad K; Berroa Garcia LY; Bradley A; Ortiz-Melendez C; Lee WJ; Christensen R; Prindiville SA; Calzone KA; Soballe PW; Hu Y; Chowdhury SA; Schwartz R; Schäffer AA; Ried T Am J Pathol; 2012 Nov; 181(5):1807-22. PubMed ID: 23062488 [TBL] [Abstract][Full Text] [Related]
20. Gene expression variation between distinct areas of breast cancer measured from paraffin-embedded tissue cores. Schobesberger M; Baltzer A; Oberli A; Kappeler A; Gugger M; Burger H; Jaggi R BMC Cancer; 2008 Nov; 8():343. PubMed ID: 19032762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]